Ann: Test Platform and COVID-19 Test receive CE Mark approval, page-58

Reading about septis inthe announcement, Early detection is critical, Dont really think the market has woken up to the fact that this test saves lives not just detects covid, Speculating every hospital treating covid patents will be wanting one of these machines.


AnteoTech has a commercialisation strategy in place to drive initial sales of EuGeni readers into key markets via the COVID-19 ART and the COVID-19/Flu A/Flu B Multiplex tests. The EuGeni reader base established from this program will be leveraged with the introduction of new tests that require rapid diagnostics to deliver critical clinical decision support and have the potential for a high level of market demand.

The first of these will be a quantitative test for Sepsis, the body’s extreme and life-threatening response to infection. The delivery of effective lifesaving treatment for Sepsis is time critical, it is difficult to diagnose Sepsis promptly and it is often missed when it could be more effectively treated, resulting in a very high global mortality rate, significantly beyond that of COVID-19 today.